Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological imprint. At the 26th International AIDS Conference (AIDS 2026), researchers reported persistent abnormalities affecting the gut, cardiovascular system, metabolism and immune function despite effective viral control. Read More
Researchers from Jacobio Pharmaceuticals Co. Ltd. recently presented preclinical data on JAB-BX600, an EGFR-directed antibody-drug conjugate (ADC) that selectively delivers a KRAS G12D inhibitor to tumor cells, allowing dual inhibition of the EGFR-KRAS pathway. Read More
Core Biomedicine Inc. has completed a $21 million series A financing and been awarded a Japan Agency for Medical Research and Development (AMED) grant to advance its lead programs through discovery and early clinical development. Read More
Torrey Pines Medicine (Shenzhen) Ltd. has completed an angel financing round as it advances next-generation ultralong-acting peptide therapeutics for metabolic diseases. Read More
Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Tianjin Hengrui Medicine Co. Ltd. have disclosed new fibroblast activation protein-α (FAPα) inhibitors covalently linked to radiolabeled chelating agents through a linker potentially useful for the treatment of cancer, inflammatory, cardiovascular disorders and more. Read More
Shape Therapeutics Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance SHP-201, the company’s lead gene therapy candidate. Read More
Researchers from Aglaeapharma Inc. and Alpherabio LLC reported the discovery and preclinical characterization of CC-10137, a nonopioid α2A-adrenergic receptor (α2AAR) agonist designed for peripheral activity. Read More
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has discovered new peroxisome proliferator-activated receptor γ (PPARγ) modulators potentially useful for the treatment of bladder cancer. Read More
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor agonists potentially useful for the treatment of schizophrenia, depression, Parkinson’s and Alzheimer’s disease. Read More
Prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA) are highly expressed in prostate tumors and exhibit greater prostate specificity than other prostate cancer antigens, reducing the risk of off-target immune responses. Researchers from Theravectys SA and Institut Pasteur reported preclinical efficacy data for Lenti-PROST-02, a novel lentiviral immunotherapy encoding immunogenic regions of PAP and PSA for the treatment of prostate cancer. Read More
Shanghai Fosun Pharmaceutical Industry Development Co. Ltd. has patented new salts of complement factor B (CFB) inhibitors potentially useful for the treatment of diabetic nephropathy, IgA nephropathy, paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, atypical hemolytic uremic syndrome and membranous nephropathy. Read More
Hainan Shibeikang Biological Medical Technology Co. Ltd. has identified new amino halogenated benzyl derivatives acting as voltage-gated sodium channel blockers potentially useful for the treatment of inflammatory disorders. Read More
Chronic liver injury promotes hepatic fibrosis through the activation of hepatic stellate cells and excessive extracellular matrix deposition, a process that can progress to cirrhosis and liver cancer. Researchers from Xiamen University used Arenarine D, a natural product isolated from the endophytic fungus Pallidocercospora crystallina, as the starting point for the development of novel antifibrotic agents. Read More
